Detail for Anidulafungin
Basic Information
DrugID 10
DrugName Anidulafungin
DrugDetail Anidulafungin or Eraxis is a semisynthetic echinocandin used as an antifungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.

http://en.wikipedia.org/wiki/Anidulafungin

http://www.drugbank.ca/drugs/DB00362

Indication For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.

http://www.drugbank.ca/drugs/DB00362

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amphotericin B Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, Knapp C, Lockhart SR, Ostrosky-Zeichner L, Walsh TJ, Marchillo K, Messer S, Welshenbaugh AR, Bastulli C, Iqbal N, Paetznick VL, Rodriguez J, Sein T. (2011) Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob Agents Chemother. 55(4):1543-8.
Cyclic peptide GS14K4 Harris MR, Coote PJ. (2010) Combination of caspofungin orwith antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56. Epub 2010 Jan 27.
Dermaseptin S3 Harris MR, Coote PJ. (2010) Combination of caspofungin orwith antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56. Epub 2010 Jan 27.
Fluconazole Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. (2002) Antifungal activities of fluconazole, caspofungin (MK0991), and(LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis. 43(1):13-7.
Itraconazole Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. (2005) In vitro synergy testing ofwith itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 49(8):3572-4.
Itraconazole Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. (2006) In vitro interactions ofwith azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 27(2):174-7.
Magainin 2 Harris MR, Coote PJ. (2010) Combination of caspofungin orwith antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56.
Nikkomycin Z Stevens DA. (2000) Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother. 44(9):2547-8.
Ranalexin Harris MR, Coote PJ. (2010) Combination of caspofungin orwith antimicrobial peptides results in potent synergistic killing of Candida albicans and Candida glabrata in vitro. Int J Antimicrob Agents. 35(4):347-56. Epub 2010 Jan 27.
Voriconazole Meletiadis J, Pournaras S, Roilides E, Walsh TJ. (2010) Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 54(2):602-9.
Voriconazole Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. (2005) In vitro synergy testing ofwith itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 49(8):3572-4.
Voriconazole Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ. (2009) Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions betweenand voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 53(6):2382-91.
Ravuconazole Cuenca-Estrella M., Alastruey-Lzquierdo A., Alcazar-Fuoli L., Bernal-Martinez L., Gomez-Lopez A., Buitrago M.J., Mellado E., Rodriguez-Tudela J.L. (2008) In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrobial Agents and Chemotherapy 52:1136-1139. DOI: 10.1128/aac.01160-07
Target
TargetName References EssentialGene? Link
1,3-beta-D-glucan-UDP glucosyltransferase No
1,3-beta-glucan synthase component FKS1 No
beta-1,3-glucan synthesis inhibitor No
PathWay
PathWay Name Path Picture
pathway